Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor
What investors should know before they dive in.
A bidding war is sizzling for this meat-centric firm, but Tyson is grazing dangerous terrain.
In the battle between consumer product firms and retailers, has the competitive edge shifted?
Most industrials are fairly valued at present, with a pocket of value in automakers.